Trial Profile
A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir+rilpivirine (Primary) ; Rilpivirine (Primary) ; Rilpivirine (Primary) ; Abacavir/dolutegravir/lamivudine; Cabotegravir; Dolutegravir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms FLAIR
- Sponsors ViiV Healthcare
- 22 Dec 2023 Results of post-hoc analysis cabotegravir plus rilpivirine long-acting results by baseline body mass index (BMI) category among patients from FLAIR, ATLAS, and ATLAS-2 M trials pooled through Week (W) 48, published in the Journal of Infectious Diseases.
- 30 Sep 2023 Results of post hoc, pooled analysis for Psychometric Validation of the Perception of Injection (PIN) Questionnaire , from NCT02951052 and NCT02938520, published in the Advances in Therapy
- 18 Aug 2023 Planned End Date changed from 8 Feb 2024 to 31 Dec 2026.